This randomized phase 2 study evaluated PX-866 combined with cetuximab in patients with advanced, refractory head and neck squamous cell cancer (HNSCC). The addition of PX-866 to cetuximab did not improve PFS, RR, or OS in patients with advanced, refractory HNSCC enrolled without molecular pre-selection.

READ FULL ARTICLE Curated publisher From Mdlinx